AI Article Synopsis

  • Dengue-associated hemophagocytic lymphohistiocytosis (HLH) is a rare but serious complication of dengue fever, marked by an overactive immune response that can be life-threatening.
  • A case study describes a patient with existing health issues who experienced severe complications, including persistent fever, abdominal pain, and organ dysfunction, which led to the HLH diagnosis due to significant lab findings.
  • The patient received intensive care with treatments like high-dose dexamethasone and plasmapheresis, highlighting the importance of recognizing HLH as a potential dengue-related complication and the need for more research on effective diagnosis and management.

Article Abstract

Dengue-associated hemophagocytic lymphohistiocytosis (HLH) is a rare presentation that can be potentially life-threatening, characterized by excessive activation of the immune system. This case report highlights the complexity of the presentation and management of a patient with multiple comorbidities who developed severe complications following a diagnosis of dengue fever. The patient presented with a persistent fever and abdominal pain alongside worsening renal and liver function. The combination of elevated serum triglyceride and ferritin levels, along with bicytopenia and the presence of splenomegaly, eventually led to a diagnosis of HLH. The patient required intensive care support, including hemodialysis, blood transfusions, and oxygen therapy. Treatment for HLH was initiated with high-dose dexamethasone and plasmapheresis, aiming to control the overactive immune response. This case highlights the need for awareness of HLH as a complication of dengue fever and emphasizes the significance of early diagnosis and treatment. It also stresses the need for further research to improve diagnostic and management strategies for HLH in dengue-endemic regions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534440PMC
http://dx.doi.org/10.7759/cureus.70895DOI Listing

Publication Analysis

Top Keywords

hemophagocytic lymphohistiocytosis
8
lymphohistiocytosis hlh
8
hlh rare
8
complication dengue
8
dengue fever
8
hlh
6
rare complication
4
dengue hemorrhagic
4
fever
4
hemorrhagic fever
4

Similar Publications

Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still's disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS.

View Article and Find Full Text PDF

Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.

Expert Rev Clin Immunol

December 2024

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Introduction: Besides cytokine release syndromes (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated HLH-like syndrome (IEC-HS) is increasingly recognized across CAR-T recipients. This emergent and fatal syndrome is difficult to separate from other disorders during the early phase, and urgently requires more integrated diagnostic and therapeutic frameworks.

Areas Covered: Existing literature has pointed out the potential role of unbridled proliferation of cytotoxic T lymphocytes, lymphopenia of natural killing cells, and hypercytokinemia in triggering the IEC-HS.

View Article and Find Full Text PDF

Secondary hemophagocytic lymphohistiocytosis (HLH) syndrome, a fatal disorder characterized by NK/T-cell deficiency, cytokine storm, and organ damage, is rare in chronic lymphocytic leukemia (CLL). Ibrutinib, the first generation of irreversible Bruton's tyrosine kinase inhibitor, has been the first-line therapy for CLL. As an off-target effect, it can also block IL-2 inducible T-cell kinase (ITK), which is essential in maintaining normal NK and T-cell functions.

View Article and Find Full Text PDF

Hemophagocytic lymphohistiocytosis is associated with disseminated tuberculosis in patients with advanced HIV infection.

J Infect

December 2024

Guangzhou Medical Research Institute of Infectious Diseases, Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510440, China. Electronic address:

View Article and Find Full Text PDF

Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Transpl Immunol

December 2024

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China. Electronic address:

Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder with poor clinical outcomes. Use of emapalumab, an IFN-γ inhibitor, enables primary HLH control in over 85 % of affected children. However, data on emapalumab use for Epstein-Barr virus-associated HLH (EBV-HLH) are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!